John Shively, Ph.D.
- CEA (carcinoembryonic Antigen) Gene Family
- Relationships of the Immune System to Fibromyalgia
John Shively, Ph.D., is a professor in the Department of Immunology & Theranostics within the Diabetes & Metabolism Research Institute at City of Hope.
Location
Duarte Cancer Center
Duarte, CA 91010
Education & Experience
Research
Laboratory
The Shively Lab specializes in studying the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) gene family. More specifically, the lab researches the use of anti-CEACAM5 antibodies for tumor imaging and therapy, as well as the role of CEACAM1 in T-cell activation, mammary epithelial cell polarization and, more recently, lipopolysaccharide binding. Dr. Shively is also exploring the role of the immune system in fibromyalgia, a widespread pain syndrome that primarily affects females.
Fibromyalgia Research
Our fibromyalgia research includes the collection of discard plasma from fibromyalgia patients who have a co-diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) and undergo multiple rounds of plasma exchange to remove autoantibodies from their plasma. The protocol supporting this study was approved by the City of Hope Institutional Review Board (IRB) in 2023 (protocol number 23444) and has accrued more than 20 patients to date.
The principal investigator on the protocol, Neal Prakash, M.D., Ph.D., is an expert in neuroinflammatory diseases. Many of the patients are recruited from a clinic in Northridge, California, run by Xavier Caro, M.D., an expert in the treatment of fibromyalgia. The clinical goals of the project are to document improvements in tender-point and overall pain scores before and after plasma exchange, along with improvements in small nerve fiber density measurements in skin biopsies.
Dr. Shively is analyzing immunoglobulin G (IgG) levels and function in the collected plasma and comparing the results with plasma controls or pooled IgG.
The Carcinoembryonic Antigen Gene Family
The CEACAM gene family comprises more than 30 genes located on chromosome 19. There are two subgroups, or clusters: one includes carcinoembryonic antigen (CEA)-related genes such as CEACAM1, and the other includes the pregnancy-specific glycoproteins (PSGs) that function in the maintenance of pregnancy.
The first group consists of cell-surface glycoproteins linked to the membrane either as type I transmembrane proteins or via a glycosylphosphatidylinositol (GPI) moiety. The second group consists of glycoproteins secreted by the placenta or fetus, hence the term "pregnancy specific." CEA was named for its discovery in fetal colon and colon carcinomas but was apparently absent in normal adult colon.
All members are part of the immunoglobulin (Ig) superfamily and have similar domain structures with a highly conserved N-domain. While it is generally accepted that CEACAM gene family members function as homophilic cell adhesion molecules, they are also targets of bacterial adhesins in a number of diseases, including Helicobacter pylori (H. pylori) infections that cause ulcers and gastric cancer.
In our own work, we use radiolabeled anti-CEA antibodies to target and treat tumors of the colon, breast, ovary and lung.
Genetically Engineered Antibodies
Genetic engineering of antibodies has enabled the creation of humanized full-length and smaller antibody fragments that retain tumor-targeting ability but clear more rapidly from the bloodstream, enabling better imaging results. These antibodies have been produced on campus in our Good Manufacturing Practice (GMP) facility by Paul Yazaki, Ph.D., and his group and studied in clinical trials under the leadership of Jeffrey Y.C. Wong, M.D., in the Department of Radiation Oncology.
For imaging, we have radiolabeled our antibodies with the positron emitter copper-64. For therapy, we have radiolabeled them with either yttrium-90, a beta emitter, or actinium-225, an alpha emitter. Actinium-225 is capable of delivering a higher biologically effective dose because of the larger size of the alpha particle compared with the beta particle emitted by yttrium-90.
We have also engineered an antibody-cytokine fusion protein, or immunocytokine, using our humanized anti-CEA antibody that incorporates interleukin-2 (IL-2) at the C-terminus of its heavy chain. We have shown that, when combined with tumor-targeted low-dose radiation, it enhances the influx and cytotoxic activity of cluster of differentiation 8 (CD8) cells while reducing the number of immunosuppressive regulatory T cells (Tregs).
This agent is now in clinical trials at City of Hope.
Lab Members
Maciej Kujawski, Ph.D.
Associate Research Scientist
Weidong Hu, Ph.D.
Assistant Research Scientist
Eric Aniogo, Ph.D.
Staff Scientist
Ken Omabe, Ph.D.
Postdoctoral fellow
Lin Li, M.S.
Staff Scientist
Patty Wong, B.S.
Staff Scientist